The Application of ^<203>Pb for Radiopharmaceuticals

^<203>Pb在放射性药物中的应用

• 批准号: 01570585
• 负责人: ANDO Atsushi
• 金额: $ 1.28万
• 依托单位: Kanazawa University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for General Scientific Research (C)
• 财政年份: 1989
• 资助国家: 日本
• 起止时间: 1989 至 1990
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-01570585/
• 关键词: Pb-203; Ga-67; Tl-201; Radiopharmaceutical; Tumor imaging agent; Tlー203; 悪性腫瘍陽性描画剤; Pb-203; 悪性腫瘍陽性描画

The radionuclide ^<203>Pb decays completely by electron capture to stable ^<203>Tl with a halfーlife of 52 hours. The present study was undertaken to investigate the application of ^<203>Pb for radiopharmaceuticals (especially tumor imaging agent).^<203>Pbーchloride solution was injected into the tumorーbearing rats, tumor-bearing mice and inflammatoryーinduced rats. These animals were killed at various time intervals from 3 hours to 48 hours. Tumor tissue and normal tissues were excised. The retention values of ^<203>Pb in the tissues were calculated against the administered dose of ^<203>Pb. The results obtained from the experiments about ^<203>Pbーcholoride were compared with previously described results of ^<67>Gaーcitrate and ^<201> Tlーchloride. In addition, bio-distribution of ^<203>Pb in animal body was observed by whole body autoradiography and that of this nuclide in tumor tissue was observed by macro-auto-radiography. Subcellular distribution of ^<203>Pb in tumor tissue was determined by the modified method of Hogeboom and Schneider.Retention values of ^<203>Pb in tumor tissue was smaller than those for ^<67>Ga, and much larger than those for ^<201>Tl. But retention values of ^<203>Pb in inflammatory tissue were smaller than those for ^<67>Ga and ^<201>Tl. The avid uptake of ^<203>Pb in bone and the uptake of this nuclide in tumor and liver were observed by whole body autoradiography. Accumulation of this nuclide in viable tumor tissue was observed by macroautoradiography.From the results described above, it was deduced that ^<203>Pbーchloride was a potential tumor imaging agent which hardly accumulated in inflammatory tissue.

放射性核素^<203>Pb通过电子捕获完全衰变为稳定的^<203>Tl，半衰期为52小时。本研究旨在探讨~（13）<203>Pb在放射性药物（特别是肿瘤显像剂）中的应用。<203>给荷瘤大鼠、荷瘤小鼠和炎症模型大鼠注射氯化铅溶液。在3小时至48小时的不同时间间隔处死这些动物。切除肿瘤组织和正常组织。根据<203>给予的^ Pb剂量计算^ Pb在组织中的保留值<203>。实验结果<203>与文献报道的<67>柠檬酸镓和<201>氯化铊的结果进行了比较。此外，还<203>用全身放射自显影法观察了~（13）Pb在动物体内的生物分布，用宏观放射自显影法观察了~（13）Pb在肿瘤组织中的生物分布。用<203>改良的Hogeboom和Schneider法测定了~（13）Pb在肿瘤组织中的亚细胞分布，~（13<203>）Pb在肿瘤组织中的滞留值小于~（13）<67>Ga，远大于~（13）<201>Tl。但<203>在炎症组织中，~（13）Pb的滞留值小于~（13）<67>Ga和~（13）<201>Tl。全身<203>放射自显影观察~（13）Pb在骨中的摄取、肿瘤和肝脏对~（13）Pb的摄取。用宏观放射自显影法观察到该核素在活的肿瘤组织中的蓄积，由此推断<203>氯化铅是一种潜在的肿瘤显像剂，在炎症组织中几乎不蓄积。

项目成果

安東 醇: "Pbー203 chlorideのがん親和性" 核医学. 26. 701 (1989)

Jun Ando：“Pb-203 氯化物的癌症亲和力”核医学 26. 701 (1989)。

Ando, Atsushi: "Accumulation of read (11) chloride (Pbー203) in malignant tumor and inflammatory lesion" Abstract Book of the 110th Annual Meeting of the Pharmaceutical Society of Japan. 4. 233 (1990)

Ando Atsushi：“恶性肿瘤和炎症病变中读（11）氯化物（Pb-203）的积累”日本药学会第110届年会摘要书4. 233（1990）。

安東 醇: "塩化鉛(Pbー203)の悪性腫瘍および炎症巣への集積" 日本薬学会第110年会講演要旨集. 4. 233 (1990)

Jun Ando：“恶性肿瘤和炎症灶中氯化铅 (Pb-203) 的积累”日本药学会第 110 届年会摘要 4. 233 (1990)。

Ando, Atsushi: "Tumor affinity of Pbーchloride (Pb-203)" Jpn. J. Nucl. Med.vol. 26. 701 (1989)

Ando，Atsushi：“氯化铅 (Pb-203) 的肿瘤亲和力”J. Nucl. 26. 701 (1989)

安東醇: "塩化鉛(Pb-3203)の癌および臓器親和性" 核医学. 26. 1080 (1989)

安东俊：“氯化铅（Pb-3203）的癌症和器官亲和性”核医学26。1080（1989）。